Mitochondrial targeting sequence variants of the CHCHD2 gene are a risk for Lewy body disorders

Neurology

Volumn 85, Issue 23, 2015, Pages 2016-2025

  Ogaki, Kotaro ^a,d   Koga, Shunsuke ^a   Heckman, Michael G ^b   Fiesel, Fabienne C ^a   Ando, Maya ^a,d   Labbé, Catherine ^a   Lorenzo Betancor, Oswaldo ^a   Moussaud Lamodière, Elisabeth L ^a   Soto Ortolaza, Alexandra I ^a   Walton, Ronald L ^a   Strongosky, Audrey J ^c   Uitti, Ryan J ^c   McCarthy, Allan ^e   Lynch, Timothy ^e   Siuda, Joanna ^f   Opala, Grzegorz ^f   Rudzinska, Monika ^f   Krygowska Wajs, Anna ^g   Barcikowska, Maria ^h   Czyzewski, Krzysztof ⁱ   Puschmann, Andreas ^j   Nishioka, Kenya ^d   Funayama, Manabu ^d   Hattori, Nobutaka ^d   Parisi, Joseph E ^k   Petersen, Ronald C ^l   Graff Radford, Neill R ^c   Boeve, Bradley F ^l   Springer, Wolfdieter ^a   Wszolek, Zbigniew K ^c   Dickson, Dennis W ^a   Ross, Owen A ^a,e,m   more..

^a Department of Neuroscience ^*  (United States)

^b Division of Biomedical Statistics and Informatics   (United States)

^c MAYO CLINIC   (United States)

^d JUNTENDO UNIVERSITY   (Japan)

^e UNIVERSITY COLLEGE DUBLIN   (Ireland)

^f MEDICAL UNIVERSITY OF SILESIA   (Poland)

^g JAGIELLONIAN UNIVERSITY   (Poland)

^h MOSSAKOWSKI MEDICAL RESEARCH CENTRE   (Poland)

ⁱ Central Hospital for the Ministry of Interior   (Poland)

^j LUND UNIVERSITY   (Sweden)

^k Laboratory Medicine   (United States)

^l MAYO CLINIC   (United States)

^m MAYO GRADUATE SCHOOL   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

COILED COIL HELIX COILED COIL HELIX DOMAIN CONTAINING 2; REGULATOR PROTEIN; UNCLASSIFIED DRUG; CHCHD2 PROTEIN, HUMAN; MITOCHONDRIAL PROTEIN; TRANSCRIPTION FACTOR;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DIFFUSE LEWY BODY DISEASE; ENHANCER REGION; EXON; FEMALE; GENE FREQUENCY; GENE LINKAGE DISEQUILIBRIUM; GENE MUTATION; GENETIC ASSOCIATION; GENETIC VARIABILITY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MITOCHONDRIAL TARGETING SIGNAL; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN LOCALIZATION; PROTEIN MOTIF; RNA SPLICING; SUBSTANTIA NIGRA; TEMPORAL CORTEX; ADOLESCENT; AMINO ACID SEQUENCE; GENE TARGETING; GENETIC VARIATION; GENETICS; LEWY BODY DISEASE; MIDDLE AGED; MITOCHONDRION; MOLECULAR GENETICS; PROCEDURES; RISK FACTOR; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; AMINO ACID SEQUENCE; FEMALE; GENE TARGETING; GENETIC VARIATION; HUMANS; LEWY BODY DISEASE; MALE; MIDDLE AGED; MITOCHONDRIA; MITOCHONDRIAL PROTEINS; MOLECULAR SEQUENCE DATA; PARKINSON DISEASE; RISK FACTORS; TRANSCRIPTION FACTORS; YOUNG ADULT;

EID: 84949507560     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0000000000002170     Document Type: Article

References (32)

1. de Rijk MC, Launer LJ, Berger K, et al. Prevalence of Parkinson's disease in Europe: a collaborative study of population-based cohorts: Neurologic Diseases in the Elderly Research Group. Neurology 2000;54:S21-S23.
2. Lesage S, Brice A. Parkinson's disease: from monogenic forms to genetic susceptibility factors. Hum Mol Genet 2009;18:R48-R59.
3. Funayama M, Ohe K, Amo T, et al. CHCHD2 mutations in autosomal dominant late-onset Parkinson's disease: a genome-wide linkage and sequencing study. Lancet Neurol 2015;14:274-282.
4. Longen S, Bien M, Bihlmaier K, et al. Systematic analysis of the twin cx(9)c protein family. J Mol Biol 2009;393: 356-368.
5. Liu Y, Clegg HV, Leslie PL, et al. CHCHD2 inhibits apoptosis by interacting with Bcl-x L to regulate Bax activation. Cell Death Differ 2015;22:1035-1046.
6. Pickrell AM, Youle RJ. The roles of PINK1, parkin, and mitochondrial fidelity in Parkinson's disease. Neuron 2015;85:257-273.
7. Haelterman NA, Yoon WH, Sandoval H, Jaiswal M, Shulman JM, Bellen HJ. A mitocentric view of Parkinson's disease. Annu Rev Neurosci 2014;37:137-159.
8. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992;55:181-184.
9. Kosaka K, Yoshimura M, Ikeda K, Budka H. Diffuse type of Lewy body disease: progressive dementia with abundant cortical Lewy bodies and senile changes of varying degree: a new disease Clin Neuropathol 1984; 3:185-192.
10. McKeith IG. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the Consortium on DLB International Workshop. J Alzheimers Dis 2006;9:417-423.
11. Li B, Leal SM. Methods for detecting associations with rare variants for common diseases: application to analysis of sequence data. Am J Hum Genet 2008;83:311-321.
12. Adzhubei IA, Schmidt S, Peshkin L, et al. A method and server for predicting damaging missense mutations. Nat Methods 2010;7:248-249.
13. Ng PC, Henikoff S. SIFT: predicting amino acid changes that affect protein function. Nucleic Acids Res 2003;31: 3812-3814.
14. Schwarz JM, Cooper DN, Schuelke M, Seelow D. MutationTaster2: mutation prediction for the deep-sequencing age. Nat Methods 2014;11:361-362.
15. Desmet FO, Hamroun D, Lalande M, Collod-Beroud G, Claustres M, Beroud C. Human splicing finder: an online bioinformatics tool to predict splicing signals. Nucleic Acids Res 2009;37:e67.
16. Wider C, Ross OA, Nishioka K, et al. An evaluation of the impact of MAPT, SNCA and APOE on the burden of Alzheimer's and Lewy body pathology. J Neurol Neurosurg Psychiatry 2012;83:424-429.
17. Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 1991;82: 239-259.
18. Thal DR, Rub U, Orantes M, Braak H. Phases of a betadeposition in the human brain and its relevance for the development of AD. Neurology 2002;58:1791-1800.
19. Montine TJ, Phelps CH, Beach TG, et al. National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease: a practical approach. Acta Neuropathol 2012;123:1-11.
20. Beach TG, White CL, Hamilton RL, et al. Evaluation of alpha-synuclein immunohistochemical methods used by invited experts. Acta Neuropathol 2008;116:277-288.
21. McKeith IG, Dickson DW, Lowe J, et al. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology 2005;65:1863-1872.
22. Uchikado H, Lin WL, DeLucia MW, Dickson DW. Alzheimer disease with amygdala Lewy bodies: a distinct form of alpha-synucleinopathy. J Neuropath Exp Neur 2006; 65:685-697.
23. Hell K. The Erv1-Mia40 disulfide relay system in the intermembrane space of mitochondria. Biochim Biophys Acta 2008;1783:601-609.
24. Baughman JM, Nilsson R, Gohil VM, Arlow DH, Gauhar Z, Mootha VK. A computational screen for regulators of oxidative phosphorylation implicates SLIRP in mitochondrial RNA homeostasis. PLoS Genet 2009;5: e1000590.
25. Aras S, Bai M, Lee I, Springett R, Huttemann M, Grossman LI. MNRR1 (formerly CHCHD2) is a biorganellar regulator of mitochondrial metabolism. Mitochondrion 2015;20:43-51.
26. Scarffe LA, Stevens DA, Dawson VL, Dawson TM. Parkin and PINK1: much more than mitophagy. Trends Neurosci 2014;37:315-324.
27. Bannwarth S, Ait-El-Mkadem S, Chaussenot A, et al. A mitochondrial origin for frontotemporal dementia and amyotrophic lateral sclerosis through CHCHD10 involvement. Brain 2014;137:2329-2345.
28. Banci L, Bertini I, Ciofi-Baffoni S, Tokatlidis K. The coiled coil-helix-coiled coil-helix proteins may be redox proteins. Febs Lett 2009;583:1699-1702.
29. Zhang M, Xi Z, Zinman L, et al. Mutation analysis of CHCHD10 in different neurodegenerative diseases. Brain 2015;138:e300.
30. Bras J, Guerreiro R, Darwent L, et al. Genetic analysis implicates APOE, SNCA and suggests lysosomal dysfunction in the etiology of dementia with Lewy bodies. Hum Mol Genet 2014;23:6139-6146.
31. Claros MG, Vincens P. Computational method to predict mitochondrially imported proteins and their targeting sequences. Eur J Biochem 1996;241:779-786.
32. Finn RD, Bateman A, Clements J, et al. Pfam: the protein families database. Nucleic Acids Res 2014;42: D222-D230.